NCT00655785View on ClinicalTrials.gov

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

VEGFR1-1084, VEGFR2-169

One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C

DRUG

Gemcitabine

Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17

Trial Locations (1)

960-1295

Fukushima Medical University Hospital, Fukushima

All Listed Sponsors
collaborator

Human Genome Center, Institute of Medical Science, University of Tokyo

OTHER

lead

Fukushima Medical University

OTHER

NCT00655785 - Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) | Biotech Hunter | Biotech Hunter